- Home
- LPTH vs LUNG Comparison
LPTH vs LUNG Comparison
Compare LPTH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- LUNG
- Stock Information
- Founded
- LPTH 1985
- LUNG 1995
- Country
- LPTH United States
- LUNG United States
- Employees
- LPTH N/A
- LUNG N/A
- Industry
- LPTH Semiconductors
- LUNG Industrial Specialties
- Sector
- LPTH Technology
- LUNG Health Care
- Exchange
- LPTH Nasdaq
- LUNG Nasdaq
- Market Cap
- LPTH 125.7M
- LUNG 106.3M
- IPO Year
- LPTH 1996
- LUNG 2020
- Fundamental
- Price
- LPTH $3.06
- LUNG $3.34
- Analyst Decision
- LPTH Strong Buy
- LUNG Buy
- Analyst Count
- LPTH 3
- LUNG 6
- Target Price
- LPTH $4.67
- LUNG $11.53
- AVG Volume (30 Days)
- LPTH 158.4K
- LUNG 420.0K
- Earning Date
- LPTH 09-18-2025
- LUNG 07-30-2025
- Dividend Yield
- LPTH N/A
- LUNG N/A
- EPS Growth
- LPTH N/A
- LUNG N/A
- EPS
- LPTH N/A
- LUNG N/A
- Revenue
- LPTH $33,626,969.00
- LUNG $87,473,000.00
- Revenue This Year
- LPTH $19.58
- LUNG $18.02
- Revenue Next Year
- LPTH $44.50
- LUNG $18.17
- P/E Ratio
- LPTH N/A
- LUNG N/A
- Revenue Growth
- LPTH 2.59
- LUNG 19.84
- 52 Week Low
- LPTH $1.04
- LUNG $2.50
- 52 Week High
- LPTH $4.42
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- LPTH 47.53
- LUNG 57.32
- Support Level
- LPTH $3.06
- LUNG $2.99
- Resistance Level
- LPTH $3.65
- LUNG $3.88
- Average True Range (ATR)
- LPTH 0.22
- LUNG 0.34
- MACD
- LPTH -0.03
- LUNG 0.10
- Stochastic Oscillator
- LPTH 34.44
- LUNG 58.46
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.